Article in Nature immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
Masaki TakaoDepartment of Clinical Laboratory and Internal Medicine, National Center of Neurology and Psychiatry (NCNP), National Center Hospital, Tokyo, Japan.
Akiyoshi KakitaDepartment of Pathology, Brain Research Institute, Niigata University, Niigata, Japan.
Marco ColonnaDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA. mcolonna@wustl.edu.ORCID http://orcid.org/0000-0001-5222-4987
Washington University in St. Louis · USNiigata University · JPInstitute of Brain and Blood Vessels · JPPeptcell (United Kingdom) · GB
Funding
The protein tyrosine kinase SYK drives innate immune responses against Alzheimer's DiseaseP01AG078106 · NIA · WASHINGTON UNIVERSITY · PI Jonathan Kipnis · 2022 to 2026
$18.4M
TREM2 IN MICROGLIA BIOLOGY AND ALZHEIMER'S DISEASERF1AG051485 · NIA · WASHINGTON UNIVERSITY · PI COLONNA, MARCO · 2015 to 2021
$3.5M
THERAPEUTIC STRATEGIES FOR ALZHEIMER'S DISEASE BASED ON TREM2 BIOLOGYRF1AG059082 · NIA · WASHINGTON UNIVERSITY · PI COLONNA, MARCO · 2019 to 2019
$2.6M
Soluble TREM2 regulation of microglial function in Alzheimer diseaseR21AG077244 · NIA · WASHINGTON UNIVERSITY · PI COLONNA, MARCO · 2022 to 2022
$431k
Japan Agency for Medical Research and Development (AMED) JP21wm0425019Ministry of Education, Culture, Sports, Science and Technology (MEXT) KAKENHI: 22H04798NIA NIH HHS P01 AG078106NIA NIH HHS R21 AG077244NIA NIH HHS RF1 AG051485NIA NIH HHS RF1 AG059082
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Publisher Correction: Human early-onset dementia caused by DAP12 deficiency reveals a unique signature of dysregulated microglia. · full record | OpenQuestion